Assenagon Asset Management S.A. Mirati Therapeutics, Inc. Transaction History

Assenagon Asset Management S.A.

$47.8 Billion
Q3 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 06, 2023	BUY	$27.8 - $45.35 $28.3 Million - $46.1 Million	1,016,858 Added 125.72%	1,825,678 $79.5 Million
Q2 2023 Jul 25, 2023	BUY	$36.13 - $49.49 $20 Million - $27.4 Million	552,860 Added 215.99%	808,820 $29.2 Million
Q1 2023 Apr 18, 2023	BUY	$36.54 - $54.26 $3.15 Million - $4.68 Million	86,175 Added 50.76%	255,960 $9.52 Million
Q4 2022 Jan 12, 2023	SELL	$41.27 - $98.62 $975,746 - $2.33 Million	-23,643 Reduced 12.22%	169,785 $7.69 Million
Q3 2022 Oct 27, 2022	SELL	$59.5 - $86.7 $39.2 Million - $57.1 Million	-658,522 Reduced 77.3%	193,428 $13.5 Million
Q2 2022 Jul 27, 2022	BUY	$39.16 - $88.71 $31.3 Million - $70.8 Million	798,528 Added 1494.75%	851,950 $57.2 Million
Q1 2022 Apr 25, 2022	SELL	$75.82 - $150.97 $2.94 Million - $5.85 Million	-38,738 Reduced 42.03%	53,422 $4.39 Million
Q4 2021 Feb 01, 2022	SELL	$132.01 - $190.29 $35.7 Million - $51.5 Million	-270,440 Reduced 74.58%	92,160 $13.5 Million
Q3 2021 Oct 19, 2021	SELL	$132.13 - $177.45 $126,712 - $170,174	-959 Reduced 0.26%	362,600 $64.1 Million
Q2 2021 Jul 15, 2021	BUY	$144.0 - $179.73 $10.4 Million - $12.9 Million	72,021 Added 24.7%	363,559 $58.7 Million
Q1 2021 Apr 26, 2021	BUY	$158.92 - $221.61 $39 Million - $54.4 Million	245,488 Added 533.09%	291,538 $49.9 Million
Q4 2020 Feb 01, 2021	SELL	$162.05 - $240.27 $13.4 Million - $19.9 Million	-82,750 Reduced 64.25%	46,050 $10.1 Million
Q3 2020 Oct 07, 2020	BUY	$113.26 - $167.27 $3.11 Million - $4.59 Million	27,426 Added 27.05%	128,800 $21.4 Million
Q2 2020 Jul 21, 2020	BUY	$72.01 - $120.39 $7.3 Million - $12.2 Million	101,374 New	101,374 $11.6 Million

Others Institutions Holding MRTX

# of Institutions

Shares Held

3.57M

Call Options Held

Put Options Held

36.6K

View Full List

About Mirati Therapeutics, Inc.

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

More about MRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

News

Stay updated on Assenagon Asset Management S.A. with notifications on news.

Account